Home
IONS
IONS News

Latest Ionis Pharmaceuticals Inc. (IONS) News on July 27, 2024

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

a day ago

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?

MT Newswires

3 days ago

Leerink Partners Upgrades Ionis Pharmaceuticals to Outperform From Market Perform, Adjusts PT to $62 From $53

Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study

Zacks

3 days ago

Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study

Ionis Pharmaceuticals reports data from Phase I/II trial of Angelman syndrome drug

Clinical Trials Arena

4 days ago

Ionis Pharmaceuticals reports data from Phase I/II trial of Angelman syndrome drug

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong

Investor's Business Daily

4 days ago

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong

MT Newswires

4 days ago

Sector Update: Health Care Stocks Higher Monday Afternoon

MT Newswires

4 days ago

Ionis Pharmaceuticals Shares Rise After Positive Results for Angelman Syndrome Drug Study

Ionis plots next steps for Angelman drug Biogen passed on

BioPharma Dive

5 days ago

Ionis plots next steps for Angelman drug Biogen passed on

Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome

PR Newswire

5 days ago

Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome

Ionis (IONS) Completes Enrolment for Rare Disease Drug Study

Zacks

7 days ago

Ionis (IONS) Completes Enrolment for Rare Disease Drug Study

Ionis to hold second quarter 2024 financial results webcast

PR Newswire

8 days ago

Ionis to hold second quarter 2024 financial results webcast

Ionis completes subject enrolment in Alexander disease treatment trial

Clinical Trials Arena

8 days ago

Ionis completes subject enrolment in Alexander disease treatment trial

MT Newswires

8 days ago

Ionis Pharmaceuticals Completes Trial Enrollment for Alexander Disease Treatment

Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease

PR Newswire

9 days ago

Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease

Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?

Zacks

14 days ago

Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?

Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome

PR Newswire

19 days ago

Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome

MT Newswires

a month ago

Stifel Adjusts Ionis Pharmaceuticals Price Target to $53 From $50, Maintains Hold Rating

FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen

Zacks

a month ago

FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen

MT Newswires

a month ago

Update: Ionis Pharmaceuticals' Shares Rise After FDA Accepts Metabolic Disorder Drug Candidate for Priority Review

MT Newswires

a month ago

Ionis Pharmaceuticals Says FDA Accepts Metabolic Disorder Drug Candidate for Priority Review

Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed

PR Newswire

a month ago

Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed

Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?

Zacks

a month ago

Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?

MT Newswires

a month ago

Ionis Pharmaceuticals Insider Sold Shares Worth $644,640, According to a Recent SEC Filing

Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug

Zacks

a month ago

Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug

MT Newswires

a month ago

Ionis Pharmaceuticals Says Otsuka Obtains Rights for Investigational Hereditary Angioedema Treatment in Asia Pacific

Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema

PR Newswire

a month ago

Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema

Ionis to present at TD Cowen Genetic Medicines & RNA Summit

PR Newswire

a month ago

Ionis to present at TD Cowen Genetic Medicines & RNA Summit

MT Newswires

a month ago

Bernstein Upgrades Ionis Pharmaceuticals to Market Perform From Underperform, Adjusts Price Target to $44 From $37

Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?

Zacks

2 months ago

Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?

Shareholders Will Probably Not Have Any Issues With Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation

Simply Wall St.

2 months ago

Shareholders Will Probably Not Have Any Issues With Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation

Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder

Benzinga

2 months ago

Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder

MT Newswires

2 months ago

Ionis Reports 'Positive Results' From Studies of Investigational Treatment for Hereditary Angioedema

Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema

PR Newswire

2 months ago

Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema

Ionis to hold donidalorsen Phase 3 data webcast

PR Newswire

2 months ago

Ionis to hold donidalorsen Phase 3 data webcast

The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics

Zacks

2 months ago

The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics

New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)

PR Newswire

2 months ago

New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)

Ionis (IONS), Biogen Down on Ending Development of ALS Drug

Zacks

2 months ago

Ionis (IONS), Biogen Down on Ending Development of ALS Drug

MT Newswires

2 months ago

Ionis Pharmaceuticals Says Potential Angelman Syndrome Therapy Improves Symptoms in Phase 1/2a Study

MT Newswires

2 months ago

Biogen, Ionis to Cease BIIB105 ALS Investigational Drug Development Following Phase 1/2 Trial Results

Biogen, Ionis shelve ALS drug following study failure

BioPharma Dive

2 months ago

Biogen, Ionis shelve ALS drug following study failure

Reuters

2 months ago

REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug

Reuters

2 months ago

Biogen, Ionis will discontinue development of their ALS drug

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

GlobeNewswire

2 months ago

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

PR Newswire

2 months ago

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome

PR Newswire

2 months ago

Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome

Ionis to host 2024 virtual Annual Meeting of Stockholders

PR Newswire

2 months ago

Ionis to host 2024 virtual Annual Meeting of Stockholders

The Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Simply Wall St.

3 months ago

The Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript

Insider Monkey

3 months ago

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript

MT Newswires

3 months ago

Wells Fargo Adjusts Ionis Pharmaceuticals Price Target to $82 From $85, Maintains Overweight Rating

Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss

Zacks

3 months ago

Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss

Ionis Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

3 months ago

Ionis Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Thomson Reuters StreetEvents

3 months ago

Q1 2024 Ionis Pharmaceuticals Inc Earnings Call

GuruFocus.com

3 months ago

Ionis Pharmaceuticals Inc (IONS) Q1 2024 Earnings Call Transcript Highlights: Key Developments ...

MT Newswires

3 months ago

Ionis Pharmaceuticals Insider Sold Shares Worth $256,277, According to a Recent SEC Filing

Morningstar Research

3 months ago

Analyst Report: Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

3 months ago

Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates

Zacks

3 months ago

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates

MT Newswires

3 months ago

Ionis Pharmaceuticals Q1 Net Loss Widens as Revenue Falls

Associated Press Finance

3 months ago

Ionis Pharmaceuticals: Q1 Earnings Snapshot

Ionis reports first quarter 2024 financial results

PR Newswire

3 months ago

Ionis reports first quarter 2024 financial results

Wall Street's Insights Into Key Metrics Ahead of Ionis Pharmaceuticals (IONS) Q1 Earnings

Zacks

3 months ago

Wall Street's Insights Into Key Metrics Ahead of Ionis Pharmaceuticals (IONS) Q1 Earnings

4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zacks

3 months ago

4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Zacks

3 months ago

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Ionis Publishes 2023 Corporate Responsibility Report

PR Newswire

3 months ago

Ionis Publishes 2023 Corporate Responsibility Report

Ionis to hold first quarter 2024 financial results webcast

PR Newswire

3 months ago

Ionis to hold first quarter 2024 financial results webcast

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

PR Newswire

4 months ago

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

Ionis to present at upcoming investor conferences

PR Newswire

4 months ago

Ionis to present at upcoming investor conferences

Ionis to hold olezarsen Phase 3 data webcast

PR Newswire

4 months ago

Ionis to hold olezarsen Phase 3 data webcast

Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?

Zacks

4 months ago

Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?

Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting

PR Newswire

4 months ago

Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting

Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?

Zacks

4 months ago

Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?

New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding

The Wall Street Journal

4 months ago

New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding

30 Biggest Biotechnology Companies in the World

Insider Monkey

4 months ago

30 Biggest Biotechnology Companies in the World

Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals

Zacks

4 months ago

Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals

Reuters

4 months ago

UPDATE 1-Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial

Reuters

4 months ago

Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial

Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH

PR Newswire

4 months ago

Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

GlobeNewswire

5 months ago

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

Ionis announces new chief global product strategy officer to lead next phase of commercial growth

PR Newswire

5 months ago

Ionis announces new chief global product strategy officer to lead next phase of commercial growth

Ionis to present at upcoming investor conferences

PR Newswire

5 months ago

Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Simply Wall St.

5 months ago

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Ionis Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Ionis Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

Morningstar Research

5 months ago

Analyst Report: Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2023 Earnings Call Transcript

Insider Monkey

5 months ago

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2023 Earnings Call Transcript

Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y

Zacks

5 months ago

Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y

Thomson Reuters StreetEvents

5 months ago

Q4 2023 Ionis Pharmaceuticals Inc Earnings Call

Ionis Pharmaceuticals Inc (IONS) Surpasses Revenue Guidance for 2023, Sets Sights on 2024 Growth

GuruFocus.com

5 months ago

Ionis Pharmaceuticals Inc (IONS) Surpasses Revenue Guidance for 2023, Sets Sights on 2024 Growth

Ionis Pharmaceuticals (IONS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

5 months ago

Ionis Pharmaceuticals (IONS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates

Zacks

5 months ago

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates

Associated Press Finance

5 months ago

Ionis Pharmaceuticals: Q4 Earnings Snapshot

Ionis reports fourth quarter and full year 2023 financial results

PR Newswire

5 months ago

Ionis reports fourth quarter and full year 2023 financial results

Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Zacks

5 months ago

Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Ionis Pharmaceuticals (IONS) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

Zacks

5 months ago

Ionis Pharmaceuticals (IONS) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome

PR Newswire

5 months ago

Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks

5 months ago

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication

Zacks

6 months ago

Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy

PR Newswire

6 months ago

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy

Ionis to hold fourth quarter and full year 2023 financial results webcast

PR Newswire

6 months ago

Ionis to hold fourth quarter and full year 2023 financial results webcast

Media layoffs: Google, Paramount, Disney, and others commit to job cuts in 2024

Yahoo Finance

6 months ago

Media layoffs: Google, Paramount, Disney, and others commit to job cuts in 2024

Exclusive-Alibaba considers sale of consumer assets including Freshippo, RT-Mart - sources

Reuters

6 months ago

Exclusive-Alibaba considers sale of consumer assets including Freshippo, RT-Mart - sources

Share on Social Networks: